Group 1 - A class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2] - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2] - The lawsuit alleges that certain financial institutions engaged in manipulative trading practices, specifically spoofing sell orders to create a false impression of Quantum's stock price decline [4] Group 2 - The defendants in the lawsuit include CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada, among others, who are accused of deceiving investors into selling shares at artificially low prices [4] - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud [5]